APOBEC3 signature mutations in chronic lymphocytic leukemia.

Rebhandl S, Huemer M, Gassner FJ, Zaborsky N, Hebenstreit D, Catakovic K, Grössinger EM, Greil R, Geisberger R. Leukemia. 2014 Sep,28(9):1929-32. doi: 10.1038/leu.2014.160. Epub 2014 May 20.

AID induces intraclonal diversity and genomic damage in CD86(+) chronic lymphocytic leukemia cells.

Huemer M, Rebhandl S, Zaborsky N, Gassner FJ, Hainzl S, Weiss L, Hebenstreit D, Greil R, Geisberger R. Eur J Immunol. 2014 Dec,44(12):3747-57. doi: 10.1002/eji.201344421. Epub 2014 Oct 18.

Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia.

Gassner FJ, Zaborsky N, Neureiter D, Huemer M, Melchardt T, Egle A, Rebhandl S, Catakovic K, Hartmann TN, Greil R, Geisberger R. Haematologica. 2014 May,99(5):67-9. doi: 10.3324/haematol.2013.098459. Epub 2014 Feb 21.

p53 Efficiently Suppresses Tumor Development in the Complete Absence of Its Cell-Cycle Inhibitory and Proapoptotic Effectors p21, Puma, and Noxa.

Valente LJ, Gray DH, Michalak EM, Pinon-Hofbauer J, Egle A, Scott CL, Janic A, Strasser A. Cell Rep. 2013 May 30,3(5):1339-45. doi: 10.1016/j.celrep.2013.04.012. Epub 2013 May 9.

Bid-ding for mercy: twisted killer in action.

Egle A, Asslaber D, Villunger A, Pinon-Hofbauer J. Cell Death and Differentiation. 2013 Jul,20(7):847-9. doi: 10.1038/cdd.2013.40.

[Autoimmune hemolysis accompanied by thrombopenia: consumption or myelodysplasia?].

Melchardt, T, Weiss, L, Egle, A, Dtsch Med Wochenschr. 2013 Oct,138(41):2093-5. doi: 10.1055/s-0033-1349586. Epub 2013 Oct 1.

CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism.

Zucchetto A, Caldana C, Benedetti D, Tissino E, Rossi FM, Hutterer E, Pozzo F, Bomben R, Dal Bo M, D’Arena G, Zaja F, Pozzato G, Di Raimondo F, Hartmann TN, Rossi D, Gaidano G, Del Poeta G, Gattei V. Blood. 2013 Nov 7,122(19):3317-21. doi: 10.1182/blood-2013-06-507335. Epub 2013 Sep 25.

MESENCHYMAL STEM CELLS RETAIN THEIR PRO-OLIGODENDROGENIC ACTIVITY DURING AGING: A RATIONALE FOR AUTOLOGOUS TRANSPLANTATION IN MULTIPLE SCLEROSIS

Rivera, FJ, Wodnar, R, Feichtner, M, Oberbauer, E, Brachtl, G, Greil, R, Rohde, E, Franklin, RJM, Aigner, L GLIA. 2013, 61: S52-S52.

Lapatinib plus Caelyx in patients with advanced or metastatic Her 2 positive breast cancer following failure of Trastuzumab therapy – A Phase II study of the Arbeitsgemeinschaft Medikamentose Tumortherapie

Pircher, M, Mlineritsch, B, Fridrik, M, Dittrich, C, Lang, A, Petru, E, Weltermann, A, Thaler, J, Hufnagl, C, Gampenrieder, SP, Ressler, S, Rinnerthaler, G, Ulmer, H, Greil, R ONKOLOGIE. 2013, 36: 159-159.

„ABCSG C-07 EXERCISE – Pilot study“: Endurance exercise to reduce the recurrence rate after adjuvant chemotherapy for colorectal cancer

Piringer, G, Fridrik, M, Fridrik, A, Zabernigg, A, Greil, R, Eisterer, W, Tschmelitsch, J, Lang, A, Gnant, M, Thaler, J ONKOLOGIE. 2013, 36: 72-72.